# US 2003/0212062 A1 · Morpholinone and morpholine derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212062 A1
- Document ID: US20030212062A1
- Status: Published application
- Kind: A1
- Application number: 10/386,083
- Filed: 2003-03-11
- Published: 2003-11-13
- Earliest claimed: 1998-12-17
- Assignees: Synaptic Pharmaceutical Corporation
- Inventors: Bharat Lagu; Dhanapalan Nagarathnam; Dake Tian; Charles Gluchowski
- Web page: https://patentgrep.com/patent/US20030212062A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 3/06: Antihyperlipidemics
- A61P 9/06: Antiarrhythmics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/08: of the prostate
- A61P 15/10: for impotence
- A61P 25/02: for peripheral neuropathies
- A61P 25/06: Antimigraine agents
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 265/32: with oxygen atoms directly attached to ring carbon atoms
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human α1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the α1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

## Claims

### Claim 1

A compound having the structure
42
where W is O, S, or NR8; wherein R8 is independently H, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
where Y is independently O or S;
where R2 is aryl or heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl; and wherein n independently is an integer from 0 to 7 inclusive;
where R3 is independently H; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl;
where R4 is H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)tN(R8)2, —(CH2)tCN, —C(Y)R8, —C(Y)N(R8)2, —CO2R8, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, C5-C7 cycloalkenyl, or phenyl or benzyl; wherein the phenyl or benzyl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl; and wherein t independently is an integer from 1 to 4 inclusive;
where R5 is H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)tN(R8)2, —(CH2)tCN, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, C5-C7 cycloalkenyl, or phenyl or benzyl; wherein the phenyl or benzyl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C2-C7 cycloalkenyl;
where R6 is H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)tN(R8)2, —(CH2)tCN, —C(Y)R8, —C(Y)N(R)2, —CO2R8, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, C5-C7 cycloalkenyl, or phenyl or benzyl; wherein the phenyl or benzyl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl;
where R7 is H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)tN(R8)2, —(CH2)tCN, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, C5-C7 cycloalkenyl, or phenyl or benzyl; wherein the phenyl or benzyl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl;
where q is an integer from 0 to 4 inclusive;
where each R8, n, and t independently is as defined above;
where R1 is
43
wherein each R9 is H; straight chained or branched C1-C7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl, or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; C5-C7 cycloalkenyl; or aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more of F; Cl; Br; I; —(CH2)nYR8; —(CH2)nC(Y)R8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; —CN; —NO2; —N(R8)2; —SO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; or C5-C7 cycloalkenyl;
wherein each R10 is H; F; —OH; —(CH2)nC(Y)R8, —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; —CN; —NO2; —N(R8)2; aryl or heteroaryl; straight chained or branched C1-C7 alkyl, hydroxyalkyl, aminoalkyl, carboxamidoalkyl, alkoxyalkyl, monofluoroalkyl, or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; or C5-C7 cycloalkenyl; wherein the alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, carboxamidoalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be substituted with one or more aryl or heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F; Cl; Br; I; —(CH2)nYR8; —(CH2)nC(Y)R8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; —CN; —NO2; —N(R8)2; —SO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl, monofluorocycloalkyl, or polyfluorocycloalkyl; or C5-C7 cycloalkenyl;
wherein each R11 is independently H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)N(R8)2, —(CH2)tCN, —C(Y)R8, —C(Y)N(R8)2, —CO2R8, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
wherein each R12 is independently H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)N(R8)2, —(CH2)tCN, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
wherein R13 is H, C1-C7 alkyl, —C(O)R2, aryl, heteroaryl, C1-C7 alkyl substituted with one or two aryl, or C1-C7 alkyl substituted with one or two heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)CO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 aminoalkyl, alkenyl, choralkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl;
wherein R14 is H, straight chained or branched C1-C7 akyl;
wherein Z is O, S, NR14, CO, CH2,
44
wherein Y1, Y2, and Y3 independently are H; F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl;
wherein each m is independently 1 or 2;
whereineach p is independently an integer from 0 to 2 inclusive;
wherein J is
45
or C2-C7 alkenyl;
wherein each R15 is independently H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)tN(R8)2, —(CH2)tCN, —C(Y)R8, —C(Y)N(R8)2, —CO2R8, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
wherein each R16 is independently H, —(CH2)tYR8, —(CH2)tC(Y)N(R8)2, —(CH2)tC(Y)R8, —(CH2)tCO2R8, —(CH2)tN(R8)2, —(CH2)tCN, straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 alkenyl or alkynyl, C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
wherein each R17 is independently H; F; —(CH2)tYR8; —(CH2)tC(Y)N(R8)2; —(CH2)tC(Y)R8; —(CH2)tCO2R8; —(CH2)tN(R8)2; —(CH2)tCN; —C(Y)R8; —C(Y)N(R8)2; —CO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl;
wherein each R18 is independently H; F; —(CH2)tYR8; —(CH2)tC(Y)N(R8)2; —(CH2)tC(Y)R8; —(CH2)tCO2R8; —(CH2)tN(R8)2; —(CH2)tCN; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl;
wherein L is S, O, or N(R8);
wherein u is an integer from 0 to 1 inclusive;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound comprises the (+) enantiomer.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound comprises the (−) enantiomer.

### Claim 4 (depends on 1)

The compound of claim 1, wherein W is O.

### Claim 5 (depends on 1)

The compound of claim 1, wherein J is
46

### Claim 6 (depends on 5)

The compound of claim 5, wherein R1 is
47

### Claim 7 (depends on 6)

The compound of claim 6,
wherein R9 is aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more of F; Cl; Br; I; —(CH2)nYR8; —(CH2)nC(Y)R8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; —CN; —NO2; —N(R8)2; —SO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl; and
wherein R10 is H; —CN; —OH; —CO2R8; aryl or heteroaryl; wherein the aryl or heteroaryl may be substituted with one or more of F; Cl; Br; I; —(CH2)nYR8; —(CH2)nC(Y)R8; (CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; —CN; —NO2; —N(R8)2; —SO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl.

### Claim 8 (depends on 7)

The compound of claim 7 having the structure:
48
wherein R2 is phenyl; wherein the phenyl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl.

### Claim 9 (depends on 8)

The compound of claim 8 wherein J is
49

### Claim 10 (depends on 9)

The compound of claim 9 wherein R1 is
50

### Claim 11 (depends on 10)

The compound of claim 10,
wherein R9 is phenyl or pyridyl, wherein the phenyl or pyridyl may be substituted with one or more of F; Cl; Br; I; —(CH2)nYR8; —(CH2)nC(Y)R8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; —CN; —NO2; —N(R8)2; —SO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl;
wherein R10 is H, —CN, —OH, —CO2R8, or phenyl; wherein the phenyl may be substituted with one or more of F; Cl; Br; I; —(CH2)nYR8; —(CH2)nC(Y)R8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8, —CN; —NO2; —N(R8)2; —SO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, or polyfluoroalkyl; and
wherein R13 is phenyl; wherein the phenyl may be substituted with one or more of F; Cl; Br; I; —CN; —NO2; —N(R8)2; —SO2R8; —(CH2)nC(Y)R8; —(CH2)nYR8; —(CH2)nC(Y)N(R8)2; —(CH2)nCO2R8; straight chained or branched C1-C7 alkyl, monofluoroalkyl, polyfluoroalkyl, or carboxamidoalkyl; straight chained or branched C2-C7 aminoalkyl, alkenyl, or alkynyl; C3-C7 cycloalkyl; or C5-C7 cycloalkenyl.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the amount of the compound is an amount from about 0.01 mg to about 800 mg.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the amount of the compound is from about 0.01 mg to about 500 mg.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the amount of the compound is from about 0.01 mg to about 250 mg.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the amount of the compound is from about 0.1 mg to about 60 mg.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the amount of the compound is from about 1 mg to about 20 mg.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein the carrier is a liquid and the composition is a solution.

### Claim 19 (depends on 12)

The pharmaceutical composition of claim 12, wherein the carrier is a solid and the composition is a tablet.

### Claim 20 (depends on 12)

The pharmaceutical composition of claim 12, wherein the carrier is a gel and the composition is a suppository.

### Claim 21 (depends on 12)

The pharmaceutical composition of claim 12, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.

### Claim 22 (depends on 1)

A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 effective to treat benign prostatic hyperplasia.

### Claim 23 (depends on 22)

A method of claim 22, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue.

### Claim 25 (depends on 24)

The method of claim 24, wherein lower urinary tract tissue is prostatic smooth muscle.

### Claim 26 (depends on 1)

A method of treating a subject suffering from high intraocular pressure which comprises administering to the subject an amount of the compound of claim 1 effective to lower intraocular pressure.

### Claim 27 (depends on 1)

A method of treating a subject suffering from a disorder associated with high cholesterol which comprises administering to the subject an amount of the compound of claim 1 effective to inhibit cholesterol synthesis.

### Claim 28 (depends on 1)

A method of treating a subject suffering from cardiac arrhythmia which comprises administering to the subject an amount of the compound of claim 1 effective to treat cardiac arrhythmia.

### Claim 29 (depends on 1)

A method of treating a subject suffering from impotency which comprises administering to the subject an amount of the compound of claim 1 effective to treat impotency.

### Claim 30 (depends on 1)

A method of treating a subject suffering from sympathetically mediated pain which comprises administering to the subject an amount of the compound of claim 1 effective to treat sympathetically mediated pain.

### Claim 31 (depends on 1)

A method of treating a subject suffering from migraine which comprises administering to the subject an amount of the compound of claim 1 effective to treat migraine.

### Claim 32 (depends on 1)

A method of treating a disease which is susceptible to treatment by antagonism of the α1a receptor which comprises administering to the subject an amount of the compound of claim 1 effective to treat the disease.

### Claim 33 (depends on 1)

A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 in combination with a 5-alpha reductase inhibitor effective to treat benign prostatic hyperplasia.

### Claim 34 (depends on 33)

The method of claim 33, wherein the 5-alpha reductase inhibitor is finasteride.

### Claim 35 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 in combination with a therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.

### Claim 36 (depends on 35)

The pharmaceutical composition of claim 35, wherein the compound is present in an amount from about 0.01 mg to about 800 mg and the therapeutically effective amount of the finasteride is about 5 mg.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the compound is present in an amount from about 0.1 mg to about 60 mg and the therapeutically effective amount of finasteride is about 5 mg.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the compound is present in an amount from about 1 mg to about 20 mg and the therapeutically effective amount of finasteride is about 5 mg.

### Claim 39 (depends on 1)

A method of relaxing lower urinary tract tissue which comprises contacting the lower urinary tract tissue with an amount of the compound of claim 1 effective to relax lower urinary tract tissue.

### Claim 40 (depends on 39)

The method of claim 39, wherein the lower urinary tract tissue is prostatic smooth muscle.

### Claim 41 (depends on 1)

A method of relaxing lower urinary tract tissue in a subject which comprises administering to the subject an amount of the compound of claim 1 effective to relax lower urinary tract tissue.

### Claim 42 (depends on 41)

The method of claim 41, wherein the lower urinary tract tissue is prostatic smooth muscle.

### Claim 43 (depends on 1)

A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 44 (depends on 1)

A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 1 with a therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.

### Claim 45 (depends on 1)

A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 46 (depends on 1)

A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 1 with a therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.
